Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2016 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Return on Capital Employed of 30.41% for Q1 2026, up 2308.0% year-over-year from 1.26% in Q1 2025, and up 38.48% quarter-over-quarter from 49.43% in Q3 2025.
Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2016 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 30.41% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2308.0% year-over-year to 30.41%; the TTM figure through Mar 2026 stood at 30.41% (up 2308.0% YoY), while the FY2023 annual figure was 46.79%, down 509.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 30.41%, up from 49.43% in the prior quarter.
- The five-year high for Return on Capital Employed was 30.41% in Q1 2026, with the low at 164.21% in Q3 2024.
- The 5-year median for Return on Capital Employed is 51.25% (2022), against an average of 57.59%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 11510 bps in 2024, then soared 11478 bps in 2025.
- Corvus Pharmaceuticals' Return on Capital Employed stood at 51.25% in 2022, then retreated by 9 bps to 55.89% in 2023, then plunged by 194 bps to 164.21% in 2024, then soared by 70 bps to 49.43% in 2025, then soared by 38 bps to 30.41% in 2026.
- Business Quant data shows CRVS's Return on Capital Employed at 30.41% in Q1 2026, 49.43% in Q3 2025, and 50.61% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | -23.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.65% |
| Mar 31, 2026 | -30.41% |
| Sep 30, 2025 | -49.43% |
| Jun 30, 2025 | -50.61% |
| Mar 31, 2025 | -53.49% |
| Sep 30, 2024 | -164.21% |
| Jun 30, 2024 | -60.02% |
| Mar 31, 2024 | -63.95% |
| Dec 31, 2023 | -55.89% |
| Sep 30, 2023 | -49.11% |
| Jun 30, 2023 | -60.35% |
| Mar 31, 2023 | -57.76% |
| Dec 31, 2022 | -51.25% |
| Sep 30, 2022 | -46.52% |
| Jun 30, 2022 | -34.90% |
| Mar 31, 2022 | -35.96% |
| Dec 31, 2021 | -36.90% |
| Sep 30, 2021 | -40.46% |
| Jun 30, 2021 | -43.83% |
| Mar 31, 2021 | -50.29% |